No change in small low ‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tsutomu Hirano Tags: Letter to the Editor Source Type: research